Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02829372 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers
A Phase 1 study, sponsored by Ichnos Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT02829372 is a Phase 1 study that was terminated before completion, run by Ichnos Sciences. The registered enrollment target is 36 participants.
The verdict
NCT02829372, a Phase 1 study, was terminated before completion, sponsored by Ichnos Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety profile and maximum tolerable dose (MTD) of GBR 1302 monotherapy in subjects with HER2 positive cancers
Interventions
- DRUG CD3/HER2 bispecific monoclonal antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-05 |
| Est. Completion | 2019-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02829372
The ClinicalTrials.gov registry entry for NCT02829372 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ichnos Sciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CD3/HER2 bispecific monoclonal antibody is the first listed.
NCT02829372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02829372 about?
NCT02829372 is a clinical study titled "Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers". The purpose of this study is to determine the safety profile and maximum tolerable dose (MTD) of GBR 1302 monotherapy in subjects with HER2 positive cancers
What is the current status of trial NCT02829372?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2016-05. Estimated completion is 2019-05.
What interventions are being tested in trial NCT02829372?
The interventions under investigation include: CD3/HER2 bispecific monoclonal antibody (DRUG).
Who is sponsoring clinical trial NCT02829372?
This trial is sponsored by Ichnos Sciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.